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A R T I C L E   I N F O A B S T R A C T 
Although there is a vast number of probiotic products commercially available due 
to their acceptability and increasing usage, their quality control has continuously 
been a major concern. This study aimed to assess some commercially available 
probiotics on the UK market for content in relation to their label claim. Seven 
products were used for the study. The bacteria content were isolated, identified 
and enumerated on selective media. The results revealed that all products 
evaluated contained viable probiotic bacteria but only three out of the seven 
products (43%) contained the claimed culture concentration or more. None of the 
multispecies product contained all the labelled probiotic bacteria. Misidentification 
of some species occurred. The results concurred with previous studies and showed 
that quality issues with commercial probiotics remain. Since probiotic activity is 
linked with probiotic concentration and is strain specific, the need exist for a global 
comprehensive legislation to control the quality of probiotics whose market is 
gaining huge momentum.  
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INTRODUCTION 
Probiotics are described as single or multispecies 
live microorganisms that when administered, 
beneficially affect the host health beyond inherent 
basic nutrition (Guarner and Schaafsma, 1998; 
Dunne et al., 1999). Interest in using probiotics is 
gaining momentum and this is for several reasons, 
including availability in several forms, better 
understanding of their mechanism of action and 
scientific evidence of health benefits (Ng et al., 2009; 
Oelschlaeger, 2010; Masood et al., 2011; Iqbal et al., 
2014). With their increased usage and 
commercialization, probiotics are still not properly 
regulated with respect to their quality control and 
effectiveness because they are considered food and 
dietary supplements not drugs (FAO/WHO, 2001, 
2002). Consequently, the quality of commercial 
probiotic products is poor and most commercial 
probiotic products do not accurately meet their label 
claim (Temmerman et al., 2001; Weese, 2002; Drago 
et al., 2004; Elliot and Teversham, 2004; Aureli et al., 
2010; Drago et al., 2010; Weese and Martin, 2011). 
For instance, a study by Weese (2002) on both 
human and veterinary probiotics reported that only 
15% of products accurately described and contained 
their claim content (Weese, 2002). Similarly, another 
study by Weese and Martin (2011), which assessed 
25 commercial probiotics used in animal health 
reported that only 4 out of 15 products that stated 
the concentration of viable content on the label, met 
their label claim. Also, Drago et al. (2010) evaluating 
commercial probiotic products available on the USA 
market in 2009 reported that only 4 out of the 13 
products fulfilled their label claim. These authors 
recommended the need for adequate control of 
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probiotic production, the periodical screening of 
probiotic products and monitoring for effect of 
storage on product quality (Drago et al., 2010). 
The aim of this study was to evaluate whether some 
probiotic food and dietary supplements available on 
the UK market contained their claimed probiotic 
bacteria and were present in quantities stated on 
their label. 
MATERIALS AND METHODS 
Seven commercial products were used in the study 
(Table 1). They were mainly purchased from local 
supermarkets or pharmacies at Brunswick Centre 
(London, UK) or from the manufacturer. After 
purchase, the products were stored appropriately in 
cool, dry places, away from light or in the fridge at 
4oC as per the information on their labels. They 
were all used before the expiry dates printed on the 
labels. 
The products were either lyophilised powders 
packed in capsules or sachet or liquid products. For 
isolation and identification of viable probiotic 
species in the products, the solid (lyophilised) 
commercial products (Biobalance Support, 
Biobalance Travel, Digestive Health and OptiBac) 
were hydrated in 3 mL de Man Rogosa and Sharpe 
broth (Oxoid, Basingstoke, UK) supplemented with 
0.05% (w/v) L-cysteine hydrochloride (MRSc 
broth). A loopful of the hydrated solid products or 
the liquid products was streaked onto MRSc agar 
plates and incubated at 37oC anaerobically using an 
Oxoid anaerobic jar with an AnaeroGen GasPak 
System (Oxoid, Basingstoke, UK). After 48 h of 
incubation, the colonies obtained, which could be 
differentiated by their morphology (size, shape and 
appearance) were sub-cultured to obtain pure 
cultures of the selected colonies. Gram staining was 
performed on the pure cultures isolated. 
Biochemical tests for identification of the bacteria 
isolated were carried out using the commercial kits 
API 50 CHL for Lactobacillus and related genera and 
API Rapid ID 32A for anaerobes. The tests were 
conducted according to the manufacturers’ 
instructions. 
For enumeration of probiotic bacteria in the 
commercial products, the content of a capsule or 
sachet of the solid products was dispersed in 10 ml 
sterile phosphate buffered saline (PBS) (pH 7.4) and 
vortexed thoroughly. Serial dilutions of the 
mixtures were made and spread-plated on MRSc 
agar. The liquid products were serially diluted and 
spread-plated on MRSc agar. The inoculated plates 
were incubated at 37oC anaerobically for 48 h. 
Colonies were counted at the end of incubation. The 
number of viable bacteria present in each product 
was expressed as colony forming units per 
capsule/sachet or volume. 
RESULTS AND DISCUSSION 
The last decade has seen a rise in usage of probiotic 
food and supplement worldwide. Although no 
agreement has been made globally in terms of how 
much viable probiotic bacteria should be consumed 
per serving or daily for health benefit, some national 
guidelines advocate that one could consume a total 
of 109 probiotic bacteria per serving or daily to effect 
a health benefit (Health Canada, 2009; Italian 
Ministry of Health, 2013). It is also globally 
recognized that the activity of probiotics is strain-
specific and that adequate number of viable 
probiotic bacteria should be maintained in a 
product throughout its shelf life although the 
number is not globally defined (FAO/WHO 2001, 
2002).  
The results of the study indicated that all the 
products evaluated contained viable probiotic 
bacteria. Almost all the products contained at least 
one probiotic bacteria indicated on their label but 
none of the multispecies product contained all the 
labelled bacteria. Only three out of the seven 
products (43%) contained the claimed culture 
concentration or more.  
According to the label, Biobalance Support, 
Biobalance Travel and Digestive Health contained 
three probiotic bacteria mixture: Lactobacillus 
acidophilus, Bifidobacterium bifidum and 
Bifidobacterium lactis. In this study only two types of 
colonies were isolated from these products. A Gram 
stain of the colonies revealed Gram-positive, 
straight, rounded end rods in chains or presented 
singularly. The API 50 CHL test established that 
both colonies were lactobacilli. 
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Table 1. Comparison of labelled culture with recovered culture. 
Product 
 
 
Form Probiotic 
species/strains 
claimed on label 
No. of viable 
probiotic species 
isolated and 
identified 
Claimed 
culture 
concentration 
Recovered 
culture 
concentration 
Actimel ® Liquid  
(milk-based) 
Lactobacillus casei DN 
114 001 (main strain), 
Lactobacillus bulgaricus 
and Streptococcus 
thermophilus 
1 1 x 1010 cfu per 
100 mL 
5.80 x 1010 cfu per 
100 mL 
Biobalance 
support 
Solid 
(capsule) 
Bifidobacterium bifidum, 
L. acidophilus, and 
Bifidobacterium lactis 
2 1.25 x 1010 cfu 
per capsule 
3.16 x 108 cfu per 
capsule 
Biobalance 
Travel 
Solid 
(capsule) 
B. bifidum, L. 
acidophilus, and B. 
lactis 
2 1 x 1010 cfu per 
capsule 
3.42 x 107 cfu per 
capsule 
Digestive 
Health 
Solid 
(capsule) 
L. acidophilus, B. 
bifidum, B. lactis 
2 1.25 x 1010 cfu 
per capsule 
2.39 x 106 cfu per 
capsule 
OptiBac Solid 
(powdered 
sachet) 
L. acidophilus Rosell-52, 
L. casaei Rosell-215, 
Lactococcus lactis 
Rosell-1058, and B. 
bifidum Rosell-71 
2 5 x 109 cfu per 
sachet 
7.84 x 108 cfu per 
sachet 
SymproveTM Liquid  
(non-milk) 
Lactobacillus rhamnosus, 
Lactobacillus plantarum, 
L. acidophilus, and 
Enterococcus faecium 
2 1 x 1010 cfu per 
50 mL 
1.04 x 1010 cfu 
per 50 mL 
Yakult® Liquid  
(milk-based) 
L. casei Shirota 1 6.5 x 109 cfu 
per 65 mL 
1.30 x 1010 cfu 
per 65 mL 
 
The API rapid ID 32A test however suggested that 
they could be bifidobacteria except one of the 
isolates of Digestive Health, which was identified as 
L. acidophilus. All three products contained fewer 
viable bacteria than claimed.  
OptiBac, which was labelled to contain L. 
acidophilus, Lactobacillus casaei, Lactococcus lactis and 
B. bifidum, also gave two isolates. The API rapid ID 
32A test suggested that the isolates were L. 
acidophilus and Bifidobacterium spp. The API 50 CHL 
however suggested that the isolates were 
Lactobacillus paracasei and L. acidophilus. The product 
also showed a lower amount of viable bacteria than 
declared (7.8 x 108 cfu per sachet versus 5 x 109 cfu 
per sachet claimed). 
SymproveTM, was labelled to contain four species: 
Lactobacillus rhamnosus, Lactobacillus plantarum, 
Lactobacillus acidophilus and Enterococcus faecium but 
only two of the species indicated on the label were 
isolated. The API 50 CHL identified the species as L. 
plantarum and L. rhamnosus. The recovered viable 
culture concentration corresponded to the label 
claim (1 x1010 per 50 mL). 
Actimel® also indicated it contained Lactobacillus 
casei DN 114 001 as the main strain. Only one type 
of colony was isolated from it. The colony was 
identified as L. paracasei with the API 50 CHL test 
kit. The other yoghurt cultures, Lactobacillus 
bulgaricus and Streptococcus thermophilus were not 
isolated. The product contained higher viable 
culture concentration than the label claim (5.8 x 1010 
cfu per 100 mL versus 1 x 1010 cfu per 100 mL). 
A single isolate was obtained from Yakult®, which 
was also labelled to contain L. casei Shirota. The 
species was identified as L. paracasei with the API 50 
CHL test kit. It contained in excess of the claimed 
culture concentration (1.3 x 1010 cfu per 65 mL 
versus 6.5 x 109 cfu per 65 mL claimed). 
The Food and Agriculture Organization (FAO) and 
World Health Organization (WHO) recommend 
that microbial species be stated on the label and the 
number of viable probiotic bacteria present at the 
end of shelf life be stated as well. Nonetheless, 
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many studies, which have evaluated the quality of 
probiotics, have shown widespread deficiencies in 
identification and enumeration and generally poor 
correlation between labelled and claimed 
(Temmerman et al., 2001; Weese, 2002; Elliot and 
Teversham, 2004; Drago et al., 2004; Lin et al., 2006; 
Aureli et al., 2010; Drago et al., 2010; Weese and 
Martin, 2011). 
Similar to the previous studies, the number of viable 
probiotic bacteria in the products, especially the 
solid products were low. This could be attributed to 
the stressful processes the cells are subjected to 
during manufacture, which may result in injury of 
the cells (Champagne et al., 2011). Moreover, 
inadequate packaging, storage and transport 
conditions after production may decrease the 
survival of the bacterial cells. This therefore 
highlights the importance of carefully selecting 
suitable species/strains that can withstand the 
manufacturing processes or selecting suitable 
manufacturing processes for selected strain. It also 
highlights the need for control of rehydration of the 
solid products as rehydration could be a critical step 
in viable cell recovery (De Valdez et al., 1985) but 
unfortunately is usually left to the discretion of the 
consumer. Furthermore, the packaging, storage and 
transport of the products must be evaluated as 
factors such as temperature, oxygen, moisture and 
light may affect the viability of the bacteria in the 
products (Morgan et al., 2006). For example, studies 
by Abadias et al. (2001), Costa et al. (2002) and 
Savini et al. (2010) have all shown the advantage of 
storing lyophilised probiotics or bacteria at 4oC than 
at room temperature, however some of the solid 
products insisted the products did not require 
refrigeration and should be stored preferably in cool 
dry places away from light. This could account for 
the low viable concentration in these products 
compared to the liquid products, which were all 
stored at 4oC. 
Probiotics properties are usually strain specific 
(Sanders and Huis in’t Veld, 1999) and therefore to 
control a cohort of diseases, which they are often 
targeted against, it was suggested that probiotic 
products should consists of a combination of strains 
(Sanders, 1993; Dunne et al., 1999; Famularo et al., 
1999; Sanders and Huis in't Veld, 1999). Multistrain 
(or multispecies) probiotic products are therefore 
commonly available preparations although practical 
superior benefit has been controversial (Chapman et 
al., 2011; Chapman et al., 2012; Tejero-Sarinena et 
al., 2013; Chapman et al., 2013). Our evaluation 
showed that none of the multispecies products 
contained all the labelled species. Only two isolates 
per product were produced and identified even 
though up to four species were declared in two 
products. The reason for this could be a result of 
inhibition amongst the species (Be'er et al., 2009; 
Chapman et al., 2012). It is also possible that some of 
the species could not grow well or were outgrown 
by other species on the selective medium used or 
that the species were not viable or were not 
included in the products. Whilst one could argue 
that the selective medium used may not cater for all 
probiotic species, it is one of the widely used 
medium in probiotic bacteria propagation and has 
received recognition by International Organisation 
for Standardization (ISO) and International Dairy 
Federation (IDF) for enumeration of lactic acid 
bacteria and bifidobacteria with antibiotic 
supplementation (ISO and IDF 2006; 2010). It is thus 
more likely the non-isolated species were inhibited, 
non-viable or not in the products.  
Bacterial identification was based on morphological 
characterization, Gram staining and biochemical 
profiling without any genotypic method which 
could be a limitation of this study. However it must 
be noted that although genotypic methods of 
identification are now fairly popular and more 
accurate, most of these sequence-based 
identification methods have a potential bias for 
detection and identification of non-viable cells. Also, 
assay cost could be high with these methods. 
Equally, the culture methods are not without 
limitations (evident in this study) but they offer the 
simplest way to detect and quantify viable 
microbes. One main challenge is the differentiation 
of colonies of various lactobacillus species in mixed 
culture. To circumvent this, the products were also 
assessed on MRSc agar supplemented with 0.002% 
w/v of bromophenol blue (which can differentiate 
between species based on characteristic pH change 
during growth; Lee and Lee, 2008) to confirm 
number of isolated species. 
Misidentification was encountered with the two 
biochemical tests; lactobacilli were identified as 
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bidifobacteria with the API Rapid ID 32A for 
anaerobes and bifidobacteria could not be identified 
at the species level. The Gram stain results however 
corroborated well with the API 50 CHL data which 
test was more detailed and rigorous, consisting of 
fermentation assays with longer growth incubation 
duration compared with the API rapid ID 32A, 
which depended on preformed enzymes by mostly 
previously lyophilised species. This 
misidentification has also been previously reported 
(Moll et al., 1996) and shows that the biochemical 
tests may not in particular accurately discern 
phenotypic variability within members of the 
different genus. 
Labelled L. casei was also identified as L. paracasei by 
the biochemical test. It must be noted that L. casei 
and L. paracasei form a closely related taxonomic 
group within the heterofermentative lactobacilli 
(Ward and Timmins, 1999). Hence these two species 
though well distinguishable from other lactobacilli 
species (except L. rhamnosus), have proven to be 
difficult to differentiate using traditional 
fermentation profiles, which often identify L. casei, 
as L. paracasei (Ward and Timmins, 1999; Yeung et 
al., 2002).  
One of the products was labelled to contain E. 
faecium. Whilst this species was not isolated from 
the product, it is not a generally regarded as safe 
(GRAS) bacterium as it is a potential pathogen in 
immunocompromised patients with high level of 
antimicrobial resistance and as such should not be 
included in probiotic products (Lund and Edlund, 
2001; FAO/WHO, 2001). 
CONCLUSIONS 
Although some limitations exist in this study, it has 
revealed some information about the quality of 
some commercial probiotics on the UK market and 
indication from the study is that the quality of 
probiotics is not improving. Probiotic activity is 
linked to the health, attribute and amount of a 
specific strain in a product. There is therefore the 
need for a worldwide legislation for the proper and 
standardized control of probiotics for quality and 
efficacy in the absence of which the quality and 
effectiveness of probiotics would continue to be 
poor. 
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